AVITA Medical OTCPK:AVHH.L Stock Report Company Financials + 10 Analysts
AVITA Medical, Inc.
OTCPK:AVHH.L Stock Report
AVHH.L Stock Overview Operates as a regenerative medicine company in the United States and internationally.
Rewards Risk Analysis See All Risk Checks AVITA Medical, Inc. Competitors Price History & Performance
Summary of all time highs, changes and price drops for AVITA Medical Historical stock prices Current Share Price US$1.88 52 Week High US$3.45 52 Week Low US$1.41 Beta 1.54 11 Month Change -0.19% 3 Month Change 1.62% 1 Year Change -28.52% 33 Year Change -44.71% 5 Year Change 384.60% Change since IPO 526.67%
Recent News & Updates
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024 Aug 09
AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales Aug 02
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
AVITA Medical, Inc. Announces Executive Changes Jul 02 See more updates
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024 Aug 09
AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales Aug 02
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
AVITA Medical, Inc. Announces Executive Changes Jul 02
AVITA Medical, Inc. Announces FDA Approval of RECELL GO May 31
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024 May 15
AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024 Apr 24
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024 Apr 12 AVITA Medical, Inc. to Report Q3, 2024 Results on May 13, 2024
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 24
AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024 Jan 10
AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 20 AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC
AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 Aug 11
AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 23 AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go Jun 30
AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients Jun 17
AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Jun 16
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects Jun 08
AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023 May 13
AVITA Medical, Inc. Announces Executive Changes May 12 AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023
AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo Dec 20
AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair Dec 13
AVITA Medical, Inc. Revises Financial Guidance for the Year 2022 Nov 11
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair Nov 10
AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 21
AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022 Oct 20
AVITA Medical, Inc. Announces Executive Changes Sep 30
AVITA Medical, Inc. Announces Chief Executive Officer Changes Sep 29
AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions Sep 13
RECELL Insurance Coverage Begins in Japan for Acute Burns Sep 02 AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System
AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 26 AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index
Avita Medical, Inc. Provides Guidance for Year 2022 May 13
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors Apr 22
AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022 Mar 01
AVITA (AVH) Announces RECELL Receives Japan PMDA Approval Feb 24
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use Feb 18
AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022 Feb 16 AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy
AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo Dec 16
AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022 Aug 27
FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment Aug 17
AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021 Jun 18
Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021 Jun 16
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients Jun 11
AVITA Medical, Inc. Provides Earnings Guidance for 2021 May 14
AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time Feb 12 AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021
AVITA Therapeutics, Inc. Appoints Kathy McGee as Chief Operating Officer, Effective December 1, 2020 Dec 01
AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation Nov 09 AVITA Therapeutics, Inc. Announces Executive Changes
AVITA Therapeutics, Inc. to Report Q1, 2021 Results on Nov 11, 2020 Oct 28
AVITA Therapeutics, Inc. to Report Q4, 2020 Results on Aug 27, 2020 Aug 14
AVITA Therapeutics Files Form 15 Jul 22 Shareholder Returns AVHH.L US Biotechs US Market 7D 0% 3.7% 5.7% 1Y -28.5% 29.2% 36.9%
See full shareholder returns
Return vs Industry: AVHH.L underperformed the US Biotechs industry which returned 29.2% over the past year.
Return vs Market: AVHH.L underperformed the US Market which returned 36.9% over the past year.
Price Volatility Is AVHH.L's price volatile compared to industry and market? AVHH.L volatility AVHH.L Average Weekly Movement n/a Biotechs Industry Average Movement 9.5% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.3% 10% least volatile stocks in US Market 3.0%
Stable Share Price: AVHH.L's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AVHH.L's volatility change over the past year.
About the Company AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
Show more AVITA Medical, Inc. Fundamentals Summary How do AVITA Medical's earnings and revenue compare to its market cap? AVHH.L fundamental statistics Market cap US$319.86m Earnings (TTM ) -US$57.32m Revenue (TTM ) US$60.04m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AVHH.L income statement (TTM ) Revenue US$60.04m Cost of Revenue US$8.61m Gross Profit US$51.43m Other Expenses US$108.75m Earnings -US$57.32m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.19 Gross Margin 85.66% Net Profit Margin -95.47% Debt/Equity Ratio 348.0%
How did AVHH.L perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
